These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 12065706)

  • 1. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.
    Walker EA; Richardson TM; Young AM
    Psychopharmacology (Berl); 1996 May; 125(2):113-9. PubMed ID: 8783384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
    Pitts RC; Allen RM; Walker EA; Dykstra LA
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-choice discrimination in pigeons is based on relative efficacy differences among opioids.
    Walker EA; Picker MJ; Dykstra LA
    Psychopharmacology (Berl); 2001 Jun; 155(4):389-96. PubMed ID: 11441428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys.
    Butelman ER; Negus SS; Lewis JW; Woods JH
    Psychopharmacology (Berl); 1996 Feb; 123(4):320-4. PubMed ID: 8867870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy.
    Negus SS; Mello NK
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1111-21. PubMed ID: 11861822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats.
    Walker EA; Richardson TM; Young AM
    Psychopharmacology (Berl); 1997 Sep; 133(1):17-28. PubMed ID: 9335076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
    White DA; Holtzman SG
    J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
    Paronis CA; Woods JH
    Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
    Zernig G; Lewis JW; Woods JH
    Psychopharmacology (Berl); 1997 Feb; 129(3):233-42. PubMed ID: 9084061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):322-30. PubMed ID: 8229759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids.
    Zhang L; Walker EA; Sutherland J; Young AM
    Psychopharmacology (Berl); 2000 Feb; 148(2):136-45. PubMed ID: 10663428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
    Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
    Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
    Walker EA; Makhay MM; House JD; Young AM
    J Pharmacol Exp Ther; 1994 Nov; 271(2):959-68. PubMed ID: 7965818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists.
    Paronis CA; Holtzman SG
    Psychopharmacology (Berl); 1994 May; 114(4):601-10. PubMed ID: 7855222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
    Barrett AC; Smith ES; Picker MJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminative stimulus effects of buprenorphine in the rat.
    Holtzman SG
    Psychopharmacology (Berl); 1997 Apr; 130(3):292-9. PubMed ID: 9151365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.
    Morgan D; Picker MJ
    Psychopharmacology (Berl); 1998 Nov; 140(1):20-8. PubMed ID: 9862398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.